Grifols snags the rest of GigaGen in $80M acquisition; Vertex moves cutting-edge diabetes treatment into the clinic
Spain’s Grifols is putting up $80 million to buy out the 56% of equity in GigaGen it doesn’t already own. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
